Favorable one-year clinical outcomes for catheter-based aortic valve replacement with latest generation of device

Findings from the PARTNER II Trial, which examined one-year clinical outcomes among high-risk or inoperable patients who received TAVR with the latest generation of balloon-expandable (SAPIEN 3) device, are being released by researchers, suggesting that the new device offers promising outcomes for patients. —> Read More